Literature DB >> 25010251

Interactions of von Willebrand factor and ADAMTS13 in von Willebrand disease and thrombotic thrombocytopenic purpura.

U Budde1, R Schneppenheim.   

Abstract

The function of von Willebrand factor (VWF), a huge multimeric protein and a key factor in platelet dependent primary haemostasis, is regulated by its specific protease ADAMTS13. The ADAMTS13 dependent degradation of VWF to its proteolytic fragments can be visualized as a characteristic so-called triplet structure of individual VWF oligomers by multimer analysis. Lack of VWF high molecular weight multimers (VWF-HMWM) or their pathologically enhanced degradation underlies a particular type of von Willebrand disease, VWD type 2A with a significant bleeding tendency, and may also be observed in acquired von Willebrand syndrome due to cardiovascular disease. In these conditions multimer analysis is an obligatory and powerful tool for diagnosis of VWD. The opposite condition, the persistence of ultralarge VWF (UL-VWF) multimers may cause the microangiopathic life-threatening disorder thrombotic thrombocytopenic purpura (TTP). During the course of active TTP, UL-VWF is consumed in the hyaline thrombi formed in the microvasculature which will ultimately result in the loss of UL-VWF and VWF-HMWM. Therefore, VWF multimer analysis is not a valid tool to diagnose TTP in the active phase of disease but may be helpful for the diagnosis of TTP patients in remission.

Entities:  

Keywords:  Triplet pattern; animal models; phenotype-genotype relation

Mesh:

Substances:

Year:  2014        PMID: 25010251     DOI: 10.5482/HAMO-13-08-0045

Source DB:  PubMed          Journal:  Hamostaseologie        ISSN: 0720-9355            Impact factor:   1.778


  8 in total

1.  Genetic variants in ADAMTS13 as well as smoking are major determinants of plasma ADAMTS13 levels.

Authors:  Qianyi Ma; Paula M Jacobi; Brian T Emmer; Colin A Kretz; Ayse Bilge Ozel; Beth McGee; Chava Kimchi-Sarfaty; David Ginsburg; Jun Z Li; Karl C Desch
Journal:  Blood Adv       Date:  2017-06-19

2.  Assessing thrombogenesis and treatment response in congenital thrombotic thrombocytopenic purpura.

Authors:  Ferras Alwan; Chiara Vendramin; Ulrich Budde; Ri Liesner; Alice Taylor; Mari Thomas; Bernhard Lämmle; Marie Scully
Journal:  EJHaem       Date:  2021-02-28

3.  Identification of extant vertebrate Myxine glutinosa VWF: evolutionary conservation of primary hemostasis.

Authors:  Marianne A Grant; David L Beeler; Katherine C Spokes; Junmei Chen; Harita Dharaneeswaran; Tracey E Sciuto; Ann M Dvorak; Gianluca Interlandi; José A Lopez; William C Aird
Journal:  Blood       Date:  2017-09-12       Impact factor: 22.113

4.  Novel protein and immune response markers of human serous tubal intraepithelial carcinoma of the ovary.

Authors:  Dmitriy W Gutkin; Michael R Shurin; Mounia Alaoui El Azher; Galina V Shurin; Liudmila Velikokhatnaya; Denise Prosser; Namhee Shin; Francesmary Modugno; Paul Stemmer; Esther Elishaev; Anna Lokshin
Journal:  Cancer Biomark       Date:  2019       Impact factor: 4.388

5.  Subsequent Response of VWF and ADAMTS13 to Aortic Valve Replacement.

Authors:  Koichi Kokame
Journal:  J Atheroscler Thromb       Date:  2016-07-29       Impact factor: 4.928

6.  ADAMTS16 mutations sensitize ovarian cancer cells to platinum-based chemotherapy.

Authors:  Maya Yasukawa; Yuexin Liu; Limei Hu; David Cogdell; Kshipra M Gharpure; Sunila Pradeep; Archana S Nagaraja; Anil K Sood; Wei Zhang
Journal:  Oncotarget       Date:  2016-08-08

Review 7.  Shear Stress-Induced Activation of von Willebrand Factor and Cardiovascular Pathology.

Authors:  Sergey Okhota; Ivan Melnikov; Yuliya Avtaeva; Sergey Kozlov; Zufar Gabbasov
Journal:  Int J Mol Sci       Date:  2020-10-21       Impact factor: 5.923

8.  Von Willebrand Factor Multimer Densitometric Analysis: Validation of the Clinical Accuracy and Clinical Implications in Von Willebrand Disease.

Authors:  Johan Boender; Ferdows Atiq; Marjon H Cnossen; Johanna G van der Bom; Karin Fijnvandraat; Joke de Meris; Moniek P M de Maat; Karin P M van Galen; Britta A P Laros-van Gorkom; Karina Meijer; Jeroen Eikenboom; Frank W G Leebeek
Journal:  Hemasphere       Date:  2021-02-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.